Joachim Bröeker

Discovery of Quinazolines as Histamine H₄Receptor Inverse Agonists Using a Scaffold Hopping Approach

Rogier A. Smits, Iwan J. P. de Esch, Obbe P. Zuiderveld et al. · Journal of Medicinal Chemistry · 2008 · 89 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Targeted Synthesis of Complex Spiro[3<i>H</i>‐indole‐3,2′‐pyrrolidin]‐2(1<i>H</i>)‐ones by Intramolecular Cyclization of Azomethine Ylides: Highly Potent MDM2–p53 Inhibitors

Andreas Gollner, Harald Weinstabl, Julian E. Fuchs et al. · ChemMedChem · 2018 · 28 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +11

Abstract 1271: <i>In vitro</i> and <i>in vivo</i> characterization of BI 1823911 - a novel KRASG12C selective small molecule inhibitor

Fabio Savarese, Andreas Gollner, Dorothea Rudolph et al. · Cancer Research · 2021 · 22 citations

Medicine, Oncology, Pharmacology +17

Chiral linker. Part 3: Synthesis and evaluation of aryl substituted m-hydrobenzoins as solid supported open chain chiral auxiliaries for the diastereoselective reduction of α-keto esters

Joachim Bröeker, M. KNOLLMUELLER, Peter Gaertner · Tetrahedron Asymmetry · 2006 · 15 citations

Natural Sciences, Chemistry, Catalysis +8

Abstract 3317: KRASmulti inhibitor BI 3706674 shows efficacy in KRAS-driven preclinical models of cancer that supports clinical testing in patients with tumors harbouring KRASG12V mutations and KRAS wild-type amplifications

Antonio Tedeschi, David H. Peng, Fiorella Schischlik et al. · Cancer Research · 2024 · 14 citations

Medicine, Molecular Biology, Oncology +13